![Göran Smedegård](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Göran Smedegård
Director/Board Member at Axcentua Pharmaceuticals AB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Fredrik Henell | M | 75 |
Axcentua Pharmaceuticals AB
![]() Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | - |
Anders Berkenstam | M | - |
Axcentua Pharmaceuticals AB
![]() Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | 17 years |
Roger William Gunnarsson | M | 77 |
Axcentua Pharmaceuticals AB
![]() Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | 15 years |
Urban Paulsson | M | 61 |
Axcentua Pharmaceuticals AB
![]() Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Robin Witt | M | - |
Axcentua Pharmaceuticals AB
![]() Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Göran Smedegård
- Personal Network